2021 Revenues ($USD) : $3,998,000,000
2021 R&D spend : $21,000,000
2021 Number of Employees : 17,300
Fiscal Year End : 6/30/2021
Leader : CEO John Chiminski

The Somerset, N.J.–based contract development and manufacturing organization (CDMO) focuses on drug delivery, biologics, drug manufacturing and gene therapies. In 2021, the company helped produce more than 1 billion COVID-19 vaccine doses. Also in 2021, the company acquired Bettera Wellness, a gummies manufacturer, to expand into the nutraceuticals market. Catalent’s biologics division had a 66% annual growth rate. After entering the cell therapy market in February 2020, the company worked in 2021 to expand its infrastructure. Catalent joined the S&P 500 index on September 21, 2020. —BB